GastroPanel® quick test can be performed during a clinical appointment from a fingertip blood drop. The new test is an advanced version of Biohit´s unique GastroPanel® stomach health test. GastroPanel® quick test differs from the current clinical test version by giving the results immediately during a single clinical appointment. The GastroPanel® quick test saves costs and unnecessary clinical appointments as well as speeds up the referral to further examinations and eventual treatment, which significantly improves the patient safety. Studies based on a long-term follow-up show consistently that the markers of GastroPanel® test indicating atrophic gastritis are highly reliable predictors of gastric cancer risk even at a 15-year time span. Similarly, the long-term negative predictive value of normal GastroPanel® test result is over 95 %, which helps identifying the high-risk persons also in a population-based screening (1). GastroPanel® quick test is a diagnostic test for stomach health on symptomatic and asymptomatic patients. GastroPanel® quick test is based on immunoassay method for GastroPanel® biomarkers in a blood sample (2). Also the results of GastroPanel® quick test are interpreted with the GastroSoft-program. GastroPanel quick test will be available in Europe as soon as the CE IVD certification process is completed.
Biohit Active B12 (holotranscoblamin) ELISA - an accurate test for measuring the levels of active vitamin B12
The traditional method of diagnosing vitamin B12 deficiency has been to measure the concentration of total vitamin-B12 in the serum. The total vitamin B12 concentration essentially reflects vitamin-B12 which is bound to its two carrier proteins forming, holohaptocorrin (holoHC) and holotranscobalamin(holoTC). Whilst holoHC accounts for 70 % - 80 % of the vitamin B12 in serum, only holoTC (active vitamin B12) can be used by human cells. Measurement of total vitamin B12 can hence give erroneous results because it measures the vitamin B12 which is in circulation but does not indicate the active vitamin B12 that is available to the cells of the body.
Biohit Active B12 test provides a solution to this diagnostic paradox: this test directly measures (holoTC) – the biochemically active form of vitamin B12 – from the human serum. This test is well suited for the screening of patients with a suspected vitamin B12 deficiency. Biohit Active B12 test can also be used for confirming the vitamin B12 status in the large number of patients who get an inconclusive result from total vitamin B12 tests.
Measures the concentration of active vitamin B12 (holotranscobalamin) available to the cells
Proven ELISA technology, support for both automated and manual analysis methods
Unlike total B12 kits, no issues with Intrinsic Factor Blocking Antibody (IFBA) interferences
Numerous clinical studies proving the performance of Active B12 over total B12
The best indicator of vitamin D status is the serum concentration of 25OH vitamin D. For a correct diagnosis of vitamin D deficiency, the assay must recognize two vitamins important in the human body, vitamin D2 and D3.
The BIOHIT Total 25OH vitamin D ELISA kit is a quantitative immunoenzymatic assay. While detecting both 25OH vitamin D2 and D3, the kit provides clinically relevant information on the vitamin D status. Reliability of the results is ensured by validation against the ID-LC/ MS-MS Reference Measurement Procedure (Ghent method) as approved by the Vitamin D Standardization Program (VDSP) with R>0.97.
Biohit Oyj is a globally operating Finnish biotechnology company. We produce innovative products and services to promote research and early diagnosis.
Innovations and patents Biohit's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.
Diagnostics The key objective of the diagnostics business is to prevent diseases of the gastrointestinal tract. Biohit HealthCare has products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel® examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer. The Acetium innovation was developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract.